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Nicotinic α4β2 receptors are the most abundant subtypes of nicotinic acetylcholine
receptors (nAChRs) expressed in brain regions implicated in obsessive compulsive
disorder (OCD). These receptors are known to modify normal and addictive behaviors
by modulating neuronal excitability. Desformylflustrabromine (dFBr) is a novel, positive
allosteric modulator (PAM) of high acetylcholine sensitivity (HS) and low acetylcholine
sensitivity (LS) α4β2 nAChRs. The present study tested the hypothesis that positive
allosteric modulation of α4β2 receptors by dFBr will attenuate compulsive-like behavior
in a non-induced compulsive-like mouse model. Male mice (Mus musculus) selected for
compulsive-like nesting behavior (NB; 48 animals; 12 per group) received acute (once)
and chronic (every day for 32 days) subcutaneous injection of dFBr at 2, 4 and 6 mg/kg
doses. Saline was used as a control (0 mg/kg). Compulsive-like NB was assessed after
1, 2, 3, 4, 5 and 24 h, while compulsive-like marble burying (MB) and anxiety-like
open field (OF) behaviors were performed 2 h after dFBr administration. In the acute
administration protocol, dFBr dose dependently attenuated NB and MB. Rapid effects
(1–2 h after drug administration) of dFBr on MB and NB were observed for the chronic
administration which was in congruence with the acute study. Chronic administration
also revealed sustained suppression of NB by dFBr following 5 weeks of treatment. In
both the acute and chronic regimen dFBr did not modulate OF behaviors. This research
demonstrates the novel role of positive allosteric modulation of α4β2 nicotinic receptors
by dFBr as a translational potential for OCD.
Keywords: desformylflustrabromine (dFBr), α4β2 nicotinic receptors, positive allosteric modulator, obsessive
compulsive disorder, non-induced compulsive-like mice
INTRODUCTION
Obsessive-compulsive disorder (OCD) is the fourth most common mental disorder (Pittenger
et al., 2005). It has a lifetime prevalence of 2.3% and a 12-month prevalence of 1.2% (Ruscio
et al., 2010). Patients suffering from OCD suffer from persistent obsessive thoughts causing
distress, and perform compulsive repetitive behaviors to alleviate uncomfortable feelings resulting
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from obsessions (Diniz et al., 2012). OCD can have disabling
effects throughout the patient’s lifespan in both males and
females (Attiullah et al., 2000).
Obsessions can be thematic, such as fear of contamination,
pathological doubt, or need for symmetry/order, or somatic
obsessions, like aggression. Repetitive compulsive behaviors
involve, washing, seeking, counting, sorting, hoarding and
searching (Doron and Moulding, 2009; Goit and Ghimire,
2014; Pauls et al., 2014). Although recently declassified as an
anxiety disorder (American Psychiatric Association, 2015), many
clinicians conceptualize OCD as a spectrum of related disorders
(OCRD) sharing common clinical features of anxiety/fear and
worry (Stein and Lochner, 2006; Storch et al., 2008; Fornaro
et al., 2009). OCRD encompasses a wide range of diseases
which includes somatoform (e.g., Hypochondriasis), impulse
control (e.g., Trichotillomania, pathological gambling) and tic
disorders (e.g., Tourette’s syndrome; Fornaro et al., 2009).
Selective serotonin reuptake inhibitors (SSRIs) and cognitive
behavioral therapy or their combination are often used as first
line treatments. However, a large group of patients remain
resistant to treatment either partially or completely (Jenike, 2004;
Pittenger et al., 2005).
The cholinergic system in the brain is comprised primarily
of nicotinic acetylcholine receptors (nAChRs; Paterson and
Nordberg, 2000; Kalamida et al., 2007) and muscarinic
acetylcholine receptors (mAChRs; Scarr, 2012; Thiele, 2013),
members of the cys-loop superfamily of ligand gated ion channels
and G protein-coupled receptors, respectively. Dysregulation of
both mAChRs and nAChRs have been strongly associated with
several neurological disorders (Janowsky et al., 1972; Freedman
et al., 1995; Warpman and Nordberg, 1995; Breese et al., 2000;
Salamone and Zhou, 2000; Perry et al., 2001; Woodruff-Pak
and Gould, 2002; Ray et al., 2005; Quik et al., 2007; Scarr,
2012).
The α4β2 nAChR is one of the most prevalent nicotinic
subtypes expressed in the brain (McGranahan et al., 2011).
The α4β2 subtype is expressed in abundance in the dopamine
pathways in the midbrain that influence the drug-induced
reward system, mood disorders, stress, movement generation
and learning (Wise, 2009; Maskos, 2010). α4β2 nAChRs have
also been identified in the striatum, thalamus and cortex
(Quik et al., 2013), brain areas implicated in OCD (Pena-
Garijo et al., 2010; Fitzgerald et al., 2011). In the striatum,
α4β2 receptors have also been shown to modulate GABA
and dopamine release (McClure-Begley et al., 2009; Perez
et al., 2012). In particular, a subtype of the α4β2 receptor
with high sensitivity to acetylcholine (HS α4β2) appears
to be involved in striatal dopamine release (Anderson
et al., 2009). These studies support a modulatory role of
α4β2 receptors in neurotransmitter release in circuits affected in
OCD.
Positive allosteric modulators (PAMs) enhance agonist
responses via increased agonist potency and/or efficacy.
Desformylflustrabromine (dFBr) is a novel PAM capable of
potentiating acetylcholine-induced whole cell responses by 370%
for the HS and 260% for the low sensitivity (LS) α4β2 receptors
with an EC50 of 40 µM and 2.5 µM respectively (Weltzin and
Schulte, 2010, 2015). It is currently the only selective PAM
for α4β2 receptors capable of potentiating the HS form of the
receptor involved in striatal dopamine release. As dFBr increases
the efficacy of acetylcholine and does not directly activate
receptors, it is postulated that its effect in the synapse would be
to enhance acetylcholine mediated transmission. Application
of dFBr, unlike application of exogenous agonists, would
thus retain the control of synaptic activation via presynaptic
release of acetylcholine, albeit with increased stimulation
(Weltzin and Schulte, 2015). Only one in vivo study has
been conducted to examine the effect of dFBr potentiation
of α4β2 nAChR in an in vivo behavioral model. In this study
dFBr was shown to attenuate nicotine self-administration in
rats (Liu, 2013). The use of HS α4β2 receptors PAMs for the
treatment of OCD has not been previously proposed or tested
in any animal model. The aim of the current study was to
evaluate our hypothesis that acute and chronic administration
of dFBr, a novel PAM specific for α4β2 nAChRs and active
at the HS α4β2 subtype, will attenuate compulsive-like and
anxiety-like behaviors in our non-induced compulsive-like
mouse model.
There are few animal models that exhibit consistent and
spontaneous differences in compulsive-like behaviors. We have
previously shown that our mice exhibit face and predictive
validity as a spontaneous non-induced model for OCD-like
behaviors (Greene-Schloesser et al., 2011). The current model
was achieved by bidirectionally selecting house mice, Mus
musculus, for nest-building behavior for 56 generations (Lynch,
1980; Bult and Lynch, 2000). The stock population for the
original selection experiment (Lynch, 1980) was a cross among
eight inbred strains, i.e., A, AKR, BLB/c, C3H/2, C57BL,
DBA/2, Is/Bi and RIII, to yield the HS/Ibg outbred strain
(McClearn Ge and Meredith, 1970; Lynch, 1980). Bidirectional
selection resulted in three levels of nesting behavior (NB). All
BIG mice exhibit consistent excessive NB engaging in rapid
and repetitive pulling of cotton through the cage top metal
bars amounting to 6–7 g of cotton on an average in 24 h
when compared to normal NB (no significant hyperactivity
and repetitiveness when introduced to cotton averaging around
0.50–0.70 g in 24 h) by the Control strain (non-compulsive) and
very little NB (most of them do not indulge in nesting) by the
SMALL strain (non-compulsive). The Control mice therefore
serve as a selection control with intermediate levels between
compulsive-like BIG and non-compulsive SMALL strains (Bult
and Lynch, 2000). NB is homologous to hoarding in humans
with OCD (Warneke, 1993), which is considered to be a measure
of compulsive-like phenotype in mice (Greene-Schloesser et al.,
2011; Wolmarans De et al., 2016). The BIG mice also uniformly
display repetitive marble burying (MB) behavior burying on an
average 19–20 marbles. Both these behaviors are significantly
attenuated by SSRIs (e.g., fluoxetine) used to treat OCD but
not with normal antidepressants (e.g., desipramine; Greene-
Schloesser et al., 2011) substantiating the face and predictive
validity of the NB and MB phenotype of the BIG mice
for investigating compulsive disorders. Hence in the current
context of investigation compulsive-like BIG mice have been
considered.
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MATERIALS AND METHODS
Animals
Compulsive-like BIG male mice, Mus musculus, were raised on
wood shavings in polypropylene cages (27 cm× 17 cm× 12 cm)
under controlled temperature (22 ± 1◦C) and light (12:12
light-dark cycle) with free access to food (Purina Mills, Lab Diet
Mouse Diet #5015, St. Louis, MO, USA) and water. Animals were
60 days of age at the start of the experiment. The University of
Alaska Fairbanks Institutional Animal Care and Use Committee
approved the animal care and experimental procedures (protocol
# 675023).
Drug Administration
Deformylflustrabromine hydrochloride (dFBr; Abcam
Biochemicals) was dissolved in physiological saline (pH = 6.7) to
yield final doses of 2 mg/kg (0.27 mg/mL), 4 mg/kg (0.53 mg/mL)
and 6 mg/kg (0.80 mg/mL). Saline was used as a vehicle control
(0 mg/kg). A mouse of 40 g received an injection volume
of 0.3 mL. Injection volumes were proportionally adjusted
according to the body weight of individual animals. All
behaviors were performed in the light phase of the light:dark
cycle. All data were recorded by an individual blinded to the
study.
Acute Study
Male BIG mice were divided into four treatment groups
comprising vehicle (sterile saline), 2 mg/kg, 4 mg/kg and
6 mg/kg. Animals in each group (n = 12 per group) were tested
for nesting on day 1, MB on day 3 and open field (OF) on day
5. On the first day of testing animals randomly received dFBr
or vehicle subcutaneously and in subsequent tests received the
same dose. Days 2 and 4 were employed to avoid any residual
effects of dFBr from previous administration. For nesting, data
were collected after 1, 2, 3, 4, 5 and 24 h due to the progressive
nature of the NB (The BIG mice typically get excited and indulge
in excessive and repetitive NB when introduced to cotton for the
first 3–4 h in the light cycle. This excessive and repetitive nesting
activity resumes again in the dark cycle). MB and OF behavior
was performed 2 h after dFBr administration (Figure 1).
Chronic Study
Since the foundation of our animal model was established
through effective reversal of compulsive-like NB and MB
behaviors by chronic fluoxetine treatment (Greene-Schloesser
et al., 2011) we also conducted a chronic regimen to establish the
sustained and long term effects of dFBr on NB and MB. Animals
belonging to 0, 2, 4 and 6 mg/kg dose group (n = 12 per group)
received single subcutaneous injection of dFBr or saline daily for
32 days. NB, MB and OF behaviors were assessed in the final
week (weeks 5) after dFBr administration (NB after 1, 2, 3 4, 5 and
24 h and MB after 2 h of drug injection). NB was performed on
day 30, MB on day 31 and OF on day 32 (Figure 1).
The dosages and route of administration was determined
based on a prior in vivo study of dFBr on rats (Liu, 2013).
Studies on rats have shown that dFBr penetrates the blood-brain
barrier and reaches the brain amounting to around 36% in the
cerebrospinal fluid after 90 min of subcutaneous administration
(Liu, 2013).
Assessment of Compulsive-Like Behaviors
Nest-Building Behavior
Nest-building behavior (NB) was performed to assess
compulsive-like behavior in the mice (Greene-Schloesser et al.,
2011). For both the acute and chronic study, compulsive-like
male mice were singly housed and provided with a pre-weighed
roll of cotton (MountainMist cotton batting, Troy, Inc., Chicago,
IL, USA) in the cage-top food hopper immediately following
subcutaneous injection of dFBr. The cotton roll was weighed
after 1, 2, 3, 4, 5 and 24 h. NB was quantified by the grams of
cotton used during each testing period (Bult and Lynch, 1996,
1997, 2000; Greene-Schloesser et al., 2011).
Marble Burying Behavior
The MB test is an effective test for determining compulsive-like
behavior in mice (Takeuchi et al., 2002; Thomas et al., 2009;
Angoa-Pérez et al., 2013). Mice generally do not interact
with the marbles and therefore the MB test measures only
digging behavior (personal observations). Two hours after dFBr
administration, compulsive-like male mice were individually
introduced to a polypropylene cage (37 cm × 21 cm × 14 cm)
containing 20 glass marbles (10 mm in diameter) evenly spaced
on 5 cm deep bedding comprised of wood shavings without
access to food or water for 20 min (Greene-Schloesser et al.,
2011). Testing was carried out in the testing room separate
from the housing room. The total number of marbles buried at
least 2/3 in the 20-min period was quantified as compulsive-like
digging behavior. After the 20-min test, the animals were
returned to their home cages.
Assessment of Locomotory and
Anxiety-Like Behavior
Open Field Test
Anxiety-like behaviors were determined in the OF test (Simon
et al., 1994; Prut and Belzung, 2003). Compulsive-like
male mice were individually introduced into an OF
(40 cm × 40 cm × 35 cm) with a central zone (20 cm × 20 cm).
The apparatus was placed underneath an overhead light
illuminating the entire OF (Greene-Schloesser et al., 2011).
The animals were placed in the center of the OF and their
behavior was video taped for 3 min and analyzed with the aid
of ANYMazeTM video tracking software (Stoelting Co., Wood
Dale, IL, USA). The time spent in the center (anxiety-like
measure) and total distance traveled (locomotion) in the entire
OF were measured. The OF was cleaned before each test. Prior
experiments (Greene-Schloesser et al., 2011) with the BIG
mice in OF indicate that a 3 min duration provides consistent
outcomes for assessment of locomotory and anxiety-like
behaviors and therefore considered for the current experiment.
Statistical Analysis
Statistical analysis was performed in Graphpad Prism (GraphPad
Software, Inc.) and Statistical Analysis System Software (SAS
Frontiers in Behavioral Neuroscience | www.frontiersin.org 3 January 2017 | Volume 10 | Article 244
Mitra et al. Modulation of nAChRs in OCD
FIGURE 1 | Schedules for behavioral assessments following Desformylflustrabromine (dFBr) administration. Top panel-Acute Study: mice in all
experimental groups (0, 2, 4 and 6 mg/kg) received subcutaneous administration of vehicle or dFBr on days 1, 3 and 5. On day 1, immediately after injections all
mice were subjected to nest-building and data were collected 1, 2, 3, 4, 5 and 24 h after injection (nest building testing schedule). On day 3 and 5 all mice were
subjected to marble burying (MB) and open field (OF) behaviors, respectively, 2 h after vehicle or dFBr injections. On days 2 and 4 mice were not given injections and
were not tested. Lower panel-Chronic study: for the chronic study mice from all groups (0, 2, 4 and 6 mg/kg) received daily single subcutaneous injections of vehicle
or dFBr for 32 days. On day 30, immediately after injection all mice were subjected to nest-building and data were collected after 1, 2, 3, 4, 5 and 24 h after injection
(nest building testing schedule). On day 31 and 32 all mice were subjected to MB and OF behaviors, respectively, 2 h after vehicle or dFBr injections.
Version 9.4, Cary, NC, USA). NB (grams of cotton), MB
(number of marbles at least 2/3 buried) and OF measures
(time in center and total distance traveled) were expressed
as the mean ± standard error of the mean (SEM). The
NB data were shown in figures as grams of cotton used,
whereas the statistical analysis was conducted on the square-root
transformed nesting scores in order to normalize the data
(Bult and Lynch, 2000). Nesting scores at different time
points, MB and OF results were analyzed by one-way analysis
of variance (ANOVA) whereas, overall drug and drug by
time interaction effect between 0 h and 5 h was done
by two-way repeated ANOVA. Pairwise comparisons for
significant differences between doses were tested by the post hoc
Bonferroni multiple comparison test. A probability level of
p < 0.05 was used as an index of statistical significance in all
cases.
RESULTS
dFBr Attenuates Compulsive-Like NB
Significant Suppression of Compulsive-Like NB
During the First 5 h of Acute dFBr Administration
(Figure 2A)
There was an overall significant drug (F(3,220) = 38.60, p< 0.0001)
effect during the first 5 h, a significant time (F(4,220) = 44.71,
p < 0.0001) and drug by time interaction effect (F(12,220) = 7.08,
p< 0.0001) in the compulsive-like NB.
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FIGURE 2 | Dose-dependent effect of dFBr on compulsive-like NB behavior in compulsive-like BIG mice (n = 12 in each group) from 1–5 h of (A) acute
and (B) chronic dFBr administration. Data are expressed as the mean ± standard error of the mean (SEM) for the amount of cotton used in grams. Statistical
significance is considered as ∗p < 0.05, ∗∗p < 0.01 ∗∗∗p < 0.001. All comparisons are with respect to control (saline).
Following a 1 h of dFBr administration, there was no
significant attenuation of nesting (F(3,44) = 1.276, not significant
(NS)). Between 1 and 2 h, dFBr administration resulted in
dose-dependent and significant reductions in nesting scores
(F(3,44) = 26.42, p < 0.0001). Post hoc assessment revealed that
4 mg/kg (t22 = 6.210, p < 0.001) and 6 mg/kg (t22 = 6.638,
p< 0.001) doses of dFBr significantly attenuatedNB as compared
to the control (saline). This effect was sustained only by 6 mg/kg
dose (t22 = 3.727, p < 0.01) between 2 and 3 h (F(3,44) = 7.906,
p < 0.0005) and both 4 and 6 mg/kg (t22 = 3.305, p < 0.05 and
t22 = 4.585, p < 0.001 respectively) between 3 and 4 h
(F(3,44) = 8.094, p < 0.0005). Between 4 and 5 h after dFBr
administration, nesting scores were not significantly different
(F(3,44) = 2.375, NS).
dFBr has an Overall Effect on NB Between 0 h and
24 h in the Acute Administration (Figure 3A)
Twenty four hours (time 0 through 24 h) after dFBr
administration, overall nesting scores were dose-dependently
and significantly reduced (F(3,44) = 7.645, p < 0.001) with the
2 mg/kg (t22 = 6.213, p< 0.001), 4 mg/kg (t22 = 9.774, p< 0.001)
and 6 mg/kg (t22 = 10.50, p < 0.001) groups significantly below
the control group.
dFBr has an Overall Effect on NB During the First 5 h
in the Chronic Administration (Figure 2B)
Significant drug (F(3,220) = 4.87, p< 0.01) time (F(4,220) = 177.12,
p < 0.0001) and drug by time interaction effect (F(12,220) = 2.29,
p < 0.01) was observed in the first 5 h of the chronic
administration.
Between 0 h and 1 h there was an overall suppression of NB
(F(3,44) = 6.52, p < 0.01) with 4 mg/kg and 6 mg/kg being the
most effective doses (t22 = 6.097, p < 0.001 and t22 = 5.394,
p< 0.001 respectively). For 1–2 h the NB declined (F(3,44) = 4.86,
p < 0.01) significantly with 2 and 6 mg/kg showing the main
attenuating effects (t22 = 3.086, p < 0.05 and t22 = 3.210,
p < 0.01 respectively). No significant effect was observed for NB
between 2–3 (F(3,44) = 1.54, NS), 3–4 (F(3,44) = 1.01, NS) and 4–5
(F(3,44) = 6.52, NS) h.
dFBr has an Overall Effect on NB Between 0 h and
24 h in the Chronic Administration (Figure 3B)
Twenty four hours (time 0 through 24 h) after dFBr
administration, overall nesting scores were dose-dependently
and significantly reduced (F(3,44) = 8.85, p < 0.0001) with the
2 mg/kg (t22 = 4.574, p < 0.05), 4 mg/kg (t22 = 7.149, p < 0.001)
and 6mg/kg (t22 = 4.555, p< 0.05) groups significantly below the
control group.
dFBr Attenuates Compulsive-Like MB
Behavior (Figure 4)
Acute Administration (Figure 4A)
MB behavior were significantly reduced (F(3,44) = 64.62,
p< 0.0001) 2 h after dFBr administration. The 2 mg/kg, 4 mg/kg
and 6 mg/kg doses decreased MB dose-dependently compared
to the control (t22 = 3.428, p < 0.01; t22 = 12.85, p < 0.001;
t22 = 7.667, p < 0.001, respectively). The 4 mg/kg and 6 mg/kg
doses also attentuated MB behavior more than the 2 mg/kg dose
(t22 = 9.426, p< 0.001 and t22 = 5.332, p< 0.001, respectively).
Chronic Administration (Figure 4B)
dFBr suppressed MB behavior significantly (F(3,44) = 40.03,
p < 0.0001) in the fifth week of administration. The most
effective doses were 4 mg/kg and 6 mg/kg which showed
the maximum suppression of MB when compared to control
(t22 = 8.643, p < 0.001; t22 = 8.554, p < 0.001, respectively).
The 4 and 6 mg/kg doses were also significantly lower than the
2 mg/kg dose (t22 = 7.039, p < 0.001; t22 = 6.950, p < 0.001,
respectively).
dFBr has no Effect on Anxiety-Like OF
Behavior (Figure 5)
Acute Administration
The total distance traveled which is used to quantify locomotor
activity was not different among the treatment groups
(F(3,44) = 1.213, NS; Figure 5A). No significant differences
were also observed among the treatment groups for the time
spent in center of the OF (F(3,44) = 0.9849, NS; Figure 5C).
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FIGURE 3 | Dose-dependent effects of dFBr on overall compulsive-like NB behavior in compulsive-like BIG mice (n = 12 in each group) 0–24 h after
(A) acute and (B) chronic dFBr administration. Data are expressed as the mean ± SEM for the amount of cotton used in grams. Statistical significance is considered
as ∗p < 0.05 and ∗∗∗p < 0.001. All comparisons are with respect to control (saline).
FIGURE 4 | Dose-dependent effect of dFBr on compulsive-like MB behavior in compulsive-like BIG mice (n = 12 in each group) 2 h after (A) acute and
(B) chronic dFBr administration. Data are expressed as the mean ± SEM for the number of marbles that are 2/3 buried. Statistical significance is considered as
∗∗p < 0.01 and ∗∗∗p < 0.001. All comparisons are with respect to control (saline).
Chronic Administration
For the chronic regimen the total distance (F(3,44) = 0.30, NS) and
time in center (F(3,44) = 0.18, NS) did not differ among treatment
groups (Figures 5B,D).
DISCUSSION
Evidence exists for cholinergic involvement in OCD (Lucey
et al., 1993; Yankelevitch-Yahav and Joel, 2013). Some studies
have indicated exacerbation of OCD symptoms induced by
nicotine (Abramovitch et al., 2015). In contrast to the higher
rates of smoking in patients with psychiatric disorders, such
as schizophrenia, bipolar disorder and ADHD, OCD patients
report less smoking behavior (Bejerot and Humble, 1999;
Bejerot et al., 2000; McCabe et al., 2004; Abramovitch et al.,
2014). It has been suggested that nicotinic activation of an
already hyperactivated fronto-striatal circuit worsens OCD
symptoms (Abramovitch et al., 2015). However, other studies
have shown that nicotine augmentation improves clinical
symptoms in patients with OCD (Carlsson, 2001; Pasquini et al.,
2005). Glutamatergic hyperactivity associated with OCD may
also be due to mediation of glutamate release by nicotinic
receptor activation. (Araki et al., 2002; Mansvelder et al.,
2002; Pasquini et al., 2005). Studies investigating cholinergic
involvement in glutamatergic hyperactivation suggest that
nicotine promotes glutamatergic transmission and stabilizes
hyperactivity of the neural circuit that originates in the
orbitofrontal cortex and projects to the cingulate gyrus, the
striatum and the thalamus (Pasquini et al., 2005). PET
and fMRI studies in OCD subjects have shown elevated
cerebral blood flow, metabolism and activation (indicators
of hyperactivity) in the orbitofrontal cortex and amygdala
in OCD (Busatto et al., 2000; Carlsson, 2000; Menzies
et al., 2008). These regions receive substantial cholinergic
innervations (Mesulam et al., 1986; Carlsson, 2000). Based on
these prior studies, we investigated the modulatory role of
α4β2 nAChRs in compulsive-like and anxiety-like behaviors in
the compulsive-like mice model.
Administration of the novel α4β2 PAM, dFBr produced a
reduction in compulsive-like NB and MB, but did not alter
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FIGURE 5 | Effect of dFBr on OF locomotory activity in (A) acute administration and (B) chronic administration. Anxiety-like time in center in OF in (C) acute
administration and (D) chronic administration in compulsive-like BIG mice (n = 12 in each group). Data are expressed as the mean ± SEM for the total distance
traveled in the OF. No statistical significance was found.
anxiety-like and locomotor activity in the OF for the acute
study. A very similar response to chronic dFBr was observed
where the treatment groups showed rapid suppression of NB
(1 h and 2 h) and MB (2 h) after dFBr administration.
OF behaviors however remained unaffected by the chronic
treatment. These results indicate an apparent selectivity of
dFBr for compulsive-like behaviors corroborating the hypothesis
that potentiation of α4β2 nAChRs could be an alternative
approach for suppressing compulsive-like phenotype thereby
posing significant translational potential.
In the acute administration, 4 mg/kg and 6 mg/kg dFBr doses
had the largest attenuating effects on NB 2 h after injection,
while for the chronic administration the suppression effects
on NB was visible after the first hour and endured in the
second hour with 6 mg/kg showing a more consistent effect.
Interestingly, an earlier effect of dFBr (1 h after administration)
on NB was observed for the chronic study indicating potential
sensitization to dFBr due to repeated treatment. The attenuating
effects gradually decreased during the next 4 h for both the
treatment, showing that dFBr had a rapid effect. This result
is consistent with the finding that peak levels of dFBr in
the cerebrospinal fluid occur 90 min after administration in
rats (Liu, 2013). The 2 mg/kg dFBr dose had no immediate
attenuating effect on NB. A long term effect of this dose was
however seen in both acute (after 24 h) and chronic (week 5)
administration indicating that this dose was effective over a
longer time period.
The effects of dFBr, 2 h after injection on MB behavior
were generally similar to the effects on NB. However, at the
2 h time point in the acute treatment 2 mg/kg moderately
and significantly reduced MB behavior. This effect was not
significant in the chronic regimen. No significant effect was
observed on NB at the same dose and time point in the acute
study but had an effect in the chronic study. These different
effects of dFBr treatment may indicate subtle differences in the
brain mechanisms that control NB and MB behavior. Clinical
studies have shown that some OCD patients with specific
types of symptoms do not respond to first line therapies in
a similar way (McKay et al., 2004). The doses that act to
attenuate obsessions and compulsions in general OCD patients
typically fail to produce results in treatment resistant ones
(Albert et al., 2013). Moreover, recommended doses for first
line treatments might vary depending on the severity of the
disorder, co-morbid symptoms like anxiety and potential side
effects (Hanna et al., 2011; Albert et al., 2013). Though, a
common agreement on OCD subtypes is lacking, therapeutic
response and results for each OCD subtype are different (Alonso
et al., 2001). For example, fluoxetine, a common OCD drug
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has greater efficacy in washers and obsessive thoughts when
compared to checkers (Farnam et al., 2008). Therefore, the
variation in dose response to dFBr of compulsive-like MB
and NB behavior adds additional heterogeneity to the BIG
mouse for assessing drug effects on various compulsive-like
phenotypes.
Acute and chronic dFBr regimen failed to modulate
anxiety-like (time spent in center) and locomotor (total
distance traveled) behaviors in the OF test. Previous studies
using the BIG mice have shown a similar effect of SSRIs
like fluoxetine, which failed to reduce overall wheel-running
locomotion in the compulsive-like BIG mice but significantly
attenuated NB and MB behavior (Greene-Schloesser et al.,
2011). Separate brain regions and signaling pathways
influencing compulsive-like and anxiety-like symptoms are
most likely the explanation for the observed lack of a dFBr
effect in the OF test. Anxiety is attributed primarily to the
amygdala and ventral hippocampus (McHugh et al., 2004),
whereas compulsions and obsessions have been linked to
dorsolateral prefrontal cortex (Hirosawa et al., 2013), anterior
cingulate cortex (Fitzgerald et al., 2005), orbitofrontal cortex
(Beucke et al., 2013) and dysregulation of the corticostriatal-
thalamo-cortical circuitry (CSTC; Ting and Feng, 2011).
These regions receive projections from the amygdala and
hippocampus (McDonald, 1991; Eblen and Graybiel, 1995;
Welch et al., 2007; Toyoda et al., 2011; Chen and Etkin,
2013) explaining the co-existence of anxiety along with
OCD, which appears to be specific to anxiety related to
compulsive-like behaviors rather than more generalized
anxiety.
Removal or inhibition by antagonists of α4β2 nAChRs
abolishes the anxiolytic effects of nicotine, while stimulating
these nAChRs receptors with an agonist decreases anxiety-like
behavior. In contrast, anxiogenic effects of nicotine withdrawal
are enhanced by stimulation of α7 nAChRs and decreased
by inhibition of these nAChRs receptors (Kutlu and Gould,
2015). Allosteric modulation of α4β2 nAChRs by dFBr did
not affect anxiety-like behavior in the OF test in the BIG
mice, suggesting that these nAChRs receptors may not be
involved in the control of anxiety in nicotine-naïve mice. A
partial agonist of α4β2 nAChRs (ABT-089) caused anxiogenic
effects in nicotine-naïve mice (Yohn et al., 2014). Whether
this result contradicts our findings or could be due to
low affinity of ABT-089 for α7 nAChRs remains to be
determined.
In summary, both acute and chronic dFBr was effective
in reversing compulsive-like NB and MB, without exerting
any influence on anxiety-like and locomotory behaviors.
This indicates the therapeutic potential of modulation of
α4β2 nAChRs by dFBr for compulsive phenotypes. Due to
the rapid rate of onset (a few hours) of the attenuating
effects of dFBr on compulsive-like behaviors, this class of
specific nicotinic subtype modulators might also provide more
immediate suppression effects thereby provide a bridging option
to other first line therapies (e.g., SSRIs) that display longer
time courses for onset of effectiveness. dFBr maintained its
attenuating effects on NB and MB during chronic treatment,
and may therefore also represent a novel first line treatment.
However, the cellular mechanisms leading to such acute
and chronic suppression of compulsive-like behavior and the
role of upstream and downstream targets that ultimately
modulate phenotypic expression of the behaviors remains
to be elucidated. It also remains to be determined if this
effect of dFBr is consistent across all rodent models of
compulsive-like phenotype. The current study thereby provides
a strong impetus for further exploration of these factors in
otherwise sparsely explored area of the role of nAChRs in
OCD.
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